

Supplementary File 1. Supplementary text

METHODS

AMASS 2.0

AMASS v2.0 was modified from AMASS v1.1.¹ The AMASS v2.0 included an additional report on notifiable bacterial diseases (Annex A) and data indicators (Annex B). Data indicators reported included blood culture contamination rate and proportion of isolates with infrequent phenotypes or potential errors in AST results.

List of notifiable bacterial diseases was derived from bacterial diseases in the National Notifiable Disease Surveillance system (Report 506) of Thailand.² The bacterial diseases included were *Burkholderia pseudomallei* infection (i.e. melioidosis), *Brucella* spp. infection, *Corynebacterium diphtheriae* infection, *Neisseria gonorrhoeae* infection, *Neisseria meningitidis* infection, *Non-typhoidal Salmonella* spp. infection, *Salmonella enterica* serovar Paratyphi infection, *Salmonella enterica* serovar Typhi infection, *Shigella* spp. infection, *Streptococcus suis* and *Vibrio* spp. infection. Each disease was defined based on culture positivity for the organism in any clinical specimen.

Blood culture contamination is defined as isolation of one or more common commensal organisms; including *Arcanobacterium* spp., *Arthrobacter* spp., *Bacillus* spp. (except *B. anthracis*), *Brevibacillus* spp., *Brevibacterium* spp., *Cellulomonas* spp., *Cellulosimicrobium* spp., *Corynebacterium* spp. (except *C. diphtheriae*, *C. jeikeium*, *C. pseudotuberculosis*, *C. striatum*, *C. ulcerans*, and *C. urealyticum*), *Cutibacterium* spp., *Dermabacter* spp., *Dermacoccus* spp., *Diphtheroids* spp., *Exiguobacterium* spp., *Geobacillus* spp., *Helcobacillus* spp., *Janibacter* spp., *Knoellia* spp., *Kocuria* spp., *Kytococcus* spp., *Leifsonia* spp., *Microbacterium* spp., *Micrococcus* spp., *Nesterenkonia* spp., *Paenibacillus* spp., *Propionibacterium* spp., *Pseudoclavibacter* spp., *Staphylococcus* spp. (except *S. aureus* and *S. lugdunensis*), *Trueperella* spp., *Virgibacillus* spp., and Viridans group *Streptococci*.³ The blood culture contamination rate is defined as the ratio of the number of blood culture contamination per number of total blood cultures.

Isolates with infrequent phenotypes or potential errors in AST results are defined using the isolate alert list of WHONET⁴ and European Committee on Antimicrobial Susceptibility Testing (EUCAST).⁵ For example, *Enterobacteriaceae* isolates with antimicrobial susceptibility test (AST) results returned as resistant to amikacin and susceptible to gentamicin would be considered as potential errors in AST results. AMASS v2.0 is open-access and available at (<https://doi.org/10.6084/m9.figshare.19771186>).

Statistical analyses

P-values were given to two significant figures, and no longer than 4 decimal places (e.g. $p < 0.0001$). Box and dot plots were used to illustrate the distribution of hospital admissions, in-hospital mortality, blood culture utilization rate and blood culture contamination rate reported by each hospital. Bar and dot plots were used to illustrate the distribution of proportion, frequency,

mortality and mortality rate of AMR BSI reported by each hospital. To represent the total burden, the bars in the figure 2 and 3 were generated by calculating the total number of numerators and denominators from all hospitals (Supplementary file 3-6).

The microbiology data files of all participating hospitals reported species of *Acinetobacter* in details (e.g. *A. baumannii*, *Acinetobacter baumannii-calcoaceticus* complex, *A. nosocomialis*, etc), except the microbiology data file of anonymous hospital no. 17, which reported all *Acinetobacter* as *Acinetobacter* spp.. In the analysis of this study, we assumed that all isolates reported as *Acinetobacter baumannii-calcoaceticus* complex reported in all participating hospitals and all isolates reported as *Acinetobacter* spp. in the anonymous hospital no. 17 were *A. baumannii*.

References

1. Lim C, Miliya T, Chansamouth V, et al. Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries. *Journal of medical Internet research* 2020; **22**(10): e19762.
2. Ministry of Public Health, Thailand. National Disease Surveillance (Report 506). <http://doe.moph.go.th/surdata/> (accessed on 19 Nov 2022).
3. Ministry of Public Health, Thailand. Manual of microbiology laboratory, 2017. (accessed on 28th December 2022).
4. WHO Collaborating Centre for Surveillance of Antimicrobial Resistance. WHONET Isolate Alerts. WHONET 2022. https://whonet.org/WebDocs/WHONET_23.Analysis_Isolate_alerts.pdf (accessed on 28 Dev 2022).
5. European Committee on Antimicrobial Susceptibility Testing. Intrinsic resistance and unusual phenotypes version 3.3. European Society of clinical Microbiology and Infectious Diseases 2021. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Expert_Rules/2021/Intrinsic_Resistance_and_Unusual_Phenotypes_Tables_v3.3_20220104.pdf (accessed on 28 Dev 2022).

Supplementary File 2. Data availability of 49 hospitals included in the analysis

Hospital	Data availability (year)	Hospital bed number	Hospital type*
Anonymous hospital No. 1	2015	446	SCH
Anonymous hospital No. 2	2012-2015	312	SCH
Anonymous hospital No. 3	2012-2015	522	TCH
Anonymous hospital No. 4	2012-2015	324	SCH
Anonymous hospital No. 5	2015	258	SCH
Anonymous hospital No. 6	2012	428	SCH
Anonymous hospital No. 7	2012-2015	310	SCH
Anonymous hospital No. 8	2013, 2014, 2015	254	SCH
Anonymous hospital No. 9	2012-2015	315	SCH
Anonymous hospital No. 10	2012-2015	832	TCH
Anonymous hospital No. 11	2012-2015	555	TCH
Anonymous hospital No. 12	2012-2013, 2015	755	TCH
Anonymous hospital No. 13	2012-2015	503	SCH
Anonymous hospital No. 14	2012, 2014	314	SCH
Anonymous hospital No. 15	2012-2015	625	TCH
Anonymous hospital No. 16	2012-2015	697	TCH
Anonymous hospital No. 17	2012-2015	1000	TCH
Anonymous hospital No. 18	2012	444	SCH
Anonymous hospital No. 19	2012-2015	867	TCH
Anonymous hospital No. 20	2012-2015	324	SCH
Anonymous hospital No. 21	2012-2015	349	SCH
Anonymous hospital No. 22	2012-2015	549	SCH
Anonymous hospital No. 23	2014-2015	505	SCH
Anonymous hospital No. 24	2012-2015	600	TCH
Anonymous hospital No. 25	2012-2015	306	SCH
Anonymous hospital No. 26	2012-2015	260	SCH
Anonymous hospital No. 27	2013-2015	411	SCH
Anonymous hospital No. 28	2014-2015	395	SCH
Anonymous hospital No. 29	2012-2015	420	SCH
Anonymous hospital No. 30	2012-2015	232	SCH
Anonymous hospital No. 31	2012-2015	360	SCH
Anonymous hospital No. 32	2015	150	SCH
Anonymous hospital No. 33	2012-2015	672	TCH
Anonymous hospital No. 34	2014-2015	334	SCH
Anonymous hospital No. 35	2012	320	SCH
Anonymous hospital No. 36	2012-2015	307	SCH
Anonymous hospital No. 37	2012-2015	878	TCH
Anonymous hospital No. 38	2012-2015	344	SCH

Anonymous hospital No. 39	2012-2015	420	SCH
Anonymous hospital No. 40	2012-2015	360	SCH
Anonymous hospital No. 41	2012-2013, 2015	210	SCH
Anonymous hospital No. 42	2012-2015	602	TCH
Anonymous hospital No. 43	2012-2015	560	TCH
Anonymous hospital No. 44	2012-2015	863	TCH
Anonymous hospital No. 45	2012-2015	215	SCH
Anonymous hospital No. 46	2012-2015	509	SCH
Anonymous hospital No. 47	2012-2015	480	SCH
Anonymous hospital No. 48	2012-2015	335	SCH
Anonymous hospital No. 49	2012-2015	527	TCH

* SCH=Secondary-care hospital; TCH=Tertiary-care hospital

Supplementary File 3. Proportion of AMR BSI

Pathogens*	Tertiary-care hospitals (n=15 hospitals)	Secondary-care hospitals (n=34 hospitals)	P value**
Community-origin BSI			
CRAB	36.9% (444/1,203)	25.0% (139/557)	0.041
CRPA	18.4% (224/1,218)	17.1% (140/821)	0.44
3GCREC	37.7% (4,462/11,845)	31.2% (3,110/9,954)	0.020
3GCRKP	24.4% (957/3,930)	19.2% (538/2,805)	0.053
CREC	0.9% (90/9,871)	1.6% (136/8,597)	0.27
CRKP	2.3% (74/3,265)	2.7% (62/2,318)	0.53
MRSA	11.7% (438/3,733)	11.2% (291/2,598)	0.46
Hospital-origin BSI			
CRAB	75.5% (2,290/3,035)	68.3% (697/1,021)	0.40
CRPA	36.7% (474/1,292)	36.7% (203/553)	0.76
3GCREC	53.9% (1,495/2,774)	53.4% (703/1,313)	0.25
3GCRKP	63.7% (1,500/2,356)	57.3% (538/939)	0.14
CREC	3.0% (66/2,230)	3.2% (38/1,176)	0.69
CRKP	9.2% (196/2,124)	8.6% (73/849)	0.84
MRSA	37.4% (634/1,695)	28.0% (249/891)	0.28

* Community-origin (Hospital-origin) BSI was defined for patients in the hospital within (longer than) the first two calendar days of admission when the first blood specimen culture positive for a pathogen were taken, with calendar day one equal to the day of admission. The proportion of AMR was defined as new AMR BSI over all patients with new BSIs for the pathogen of interest. Those who were not tested for the antibiotic of interest were not included. **The comparison was made using mixed-effect logistic regression models of patients nested within hospitals.

Supplementary File 4. Frequency of AMR BSI per 100,000 admissions

Pathogens*	Tertiary-care hospitals (n of admissions = 3,134,815)	Secondary-care hospitals (n of admissions = 2,867,762)	Incidence rate ratio (95% confidence interval)**	P value**
Community-origin BSI (per 100,000 admissions)				
CRAB	14.2 (n=444)	4.8 (n=139)	2.92 (1.87-4.56)	<0.0001
CRPA	7.1 (n=224)	4.9 (n=140)	1.49 (0.88-2.53)	0.062
3GCREC	142.3 (n=4,462)	108.4 (n=3,110)	1.33 (1.03-1.73)	0.070
3GCRKP	30.5 (n=957)	18.8 (n=538)	1.57 (1.17-2.11)	0.0017
CREC	2.9 (n=90)	4.7 (n=136)	0.68 (0.39-1.17)	0.16
CRKP	2.4 (n=74)	2.2 (n=62)	1.10 (0.59-2.03)	0.77
MRSA	14.0 (n=438)	10.1 (n=291)	1.42 (0.81-2.47)	0.22
Hospital-origin BSI (per 100,000 admissions)				
CRAB	73.1 (n=2,290)	24.3 (n=697)	3.10 (1.90-5.06)	<0.0001
CRPA	15.1 (n=474)	7.1 (n=203)	2.42 (1.36-4.32)	0.0026
3GCREC	47.7 (n=1,495)	24.5 (n=703)	1.99 (1.40-2.82)	0.0001
3GCRKP	47.8 (n=1,500)	18.7 (n=538)	2.49 (1.70-3.64)	<0.0001
CREC	2.1 (n=66)	1.3 (n=38)	1.66 (0.77-3.58)	0.20
CRKP	6.3 (n=196)	2.5 (n=73)	2.35 (1.10-5.00)	0.027
MRSA	20.2 (n=634)	8.7 (n=249)	2.12 (1.30-3.45)	0.0025

* Community-origin (Hospital-origin) BSI was defined for patients in the hospital within (longer than) the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. **The comparison was made using mixed-effect Poisson regression models of patients nested within hospitals.

Supplementary File 5. Frequency of AMR BSI per 100,000 patient-days at risk

Pathogens*	Tertiary-care hospitals (n of patient-days at risk = 12,341,585)	Secondary-care hospitals (n of patient-days at risk = 9,988,198)	Incidence rate ratio (95% confidence interval)**	P value**
Hospital-origin BSI (per 100,000 patient-days at risk)				
CRAB	18.6 (n=2,290)	7.0 (n=697)	2.77 (1.72-4.43)	<0.0001
CRPA	3.8 (n=474)	2.0 (n=203)	2.14 (1.22-3.74)	0.0073
3GCREC	12.1 (n=1,495)	7.0 (n=703)	1.79 (1.29-2.50)	0.0005
3GCRKP	12.2 (n=1,500)	5.4 (n=538)	2.23 (1.57-3.17)	<0.0001
CREC	0.5 (n=66)	0.4 (n=38)	1.41 (0.65-3.06)	0.39
CRKP	1.6 (n=196)	0.7 (n=73)	2.10 (1.01-4.35)	0.045
MRSA	5.1 (n=634)	2.5 (n=249)	1.88 (1.17-3.01)	0.0091

* Hospital-origin BSI was defined for patients in the hospital longer than the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. Patients were considered at risk of hospital-origin BSI after they stayed in the hospital for more than two calendar days. **The comparison was made using mixed-effect Poisson regression models of patients nested within hospitals.

Supplementary File 6. Frequency of AMR BSI per 100,000 tested patients

Pathogens*	Tertiary-care hospitals (n of tested patients = 191,399)	Secondary-care hospitals (n of tested patients = 206,572)	Incidence rate ratio (95% confidence interval)**	P value**
Community-origin BSI (per 100,000 tested patients)				
CRAB	107.1 (n=150)	49.4 (n=102)	2.22 (1.26-3.92)	0.006
CRPA	54.3 (n=104)	47.0 (n=97)	1.23 (0.57-2.69)	0.59
3GCREC	1191.8 (n=2,281)	1119.7 (n=2,313)	0.97 (0.64-1.49)	0.91
3GCRKP	274.3 (n=525)	179.6 (n=371)	1.43 (0.99-2.07)	0.059
CREC	24.0 (n=46)	55.2 (n=114)	0.50 (0.22-1.12)	0.091
CRKP	20.9 (n=40)	23.7 (n=49)	0.86 (0.37-2.03)	0.73
MRSA	133.2 (n=255)	107.5 (n=222)	1.25 (0.66-2.39)	0.48
	Tertiary-care hospitals (n of tested patients = 50,603)	Secondary-care hospitals (n of tested patients = 41,441)	Incidence rate ratio (95% confidence interval)**	P value**
Hospital-origin BSI (per 100,000 tested patients)				
CRAB	1,991.3 (n=733)	1,201.7 (n=498)	1.89 (1.06-3.37)	0.032
CRPA	584.9 (n=296)	345.1 (n=143)	1.81 (0.91-3.61)	0.091
3GCREC	1,671.8 (n=846)	1,158.3 (n=480)	1.43 (0.97-2.09)	0.069
3GCRKP	1,774.6 (n=898)	851.8 (n=353)	2.10 (1.47-3.00)	<0.0001
CREC	83.0 (n=42)	74.8 (n=31)	1.10 (0.52-2.36)	0.81
CRKP	252.9 (n=128)	113.4 (n=47)	2.32 (1.07-5.03)	0.033
MRSA	743.0 (n=376)	381.3 (n=158)	1.72 (1.00-2.96)	0.049

* Community-origin (Hospital-origin) BSI was defined for patients in the hospital within (longer than) the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. Frequency of AMR BSI per 100,000 tested patients were estimated in 23 SCHs and 7 TCHs of which the microbiology data obtained included the culture result of “no growth”. **The comparison was made using mixed-effect Poisson regression models of patients nested within hospitals.

Supplementary File 7. In-hospital mortality of patients with AMR BSI

Pathogens *	Tertiary-care hospitals (n=15 hospitals)	Secondary-care hospitals (n=34 hospitals)	P value **
Community-origin BSI			
CRAB	48.0% (213/444)	47.5% (66/139)	0.93
CRPA	26.8% (60/224)	30.0% (42/140)	0.95
3GCREC ***	23.8% (1,048/4,399)	22.5% (681/3,032)	0.46
3GCRKP ***	30.8% (275/894)	28.3% (140/495)	0.28
CREC	28.9% (26/90)	29.4% (40/136)	0.93
CRKP	37.8% (28/74)	27.4% (17/62)	0.20
MRSA	33.3% (146/438)	31.3% (91/291)	0.83
Hospital-origin BSI			
CRAB	55.1% (1,261/2,290)	51.9% (362/697)	0.88
CRPA	42.6% (202/474)	40.9% (83/203)	0.86
3GCREC ***	34.6% (496/1,434)	35.0% (236/675)	0.88
3GCRKP ***	38.1% (497/1,306)	37.3% (176/472)	0.74
CREC	39.4% (26/66)	42.1% (16/38)	0.71
CRKP	49.0% (96/196)	41.1% (30/73)	0.38
MRSA	44.6% (283/634)	43.8% (109/249)	0.75

* Community-origin (Hospital-origin) BSI was defined for patients in the hospital within (longer than) the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. In-hospital mortality (%) of AMR BSI was calculated as the percentage of patients with new AMR BSI who died in the hospitals. Those who were not tested for the antibiotic of interest were not included.

The comparison was made using mixed-effect logistic regression models of patients nested within hospitals. * For the analysis of mortality, patients with 3GCREC BSI did not include patients with CREC BSI, and patients with 3GCRKP did not include patients with CRKP BSI.

Supplementary File 8. Mortality rate of AMR BSI per 100,000 admissions

Pathogens *	Tertiary-care hospitals (n of admissions = 3,134,815)	Secondary-care hospitals (n of admissions = 2,867,762)	Mortality rate ratio (95% confidence interval) **	P value **
Community-origin BSI (per 100,000 admissions)				
CRAB	6.8 (n=213)	2.3 (n=66)	2.92 (1.65-5.19)	<0.0001
CRPA	1.9 (n=60)	1.5 (n=42)	1.45 (0.70-3.00)	0.32
3GCREC ***	33.4 (n=23)	23.7 (n=681)	1.40 (0.97-2.01)	0.069
3GCRKP ***	8.8 (n=275)	4.9 (n=140)	1.79 (1.28-2.52)	<0.0001
CREC	0.8 (n=26)	1.4 (n=40)	0.62 (0.33-1.16)	0.14
CRKP	0.9 (n=28)	0.6 (n=17)	1.54 (0.73-3.27)	0.25
MRSA	4.7 (n=146)	3.2 (n=91)	1.47 (0.71-3.02)	0.30
Hospital-origin BSI (per 100,000 admissions)				
CRAB	40.2 (n=1,261)	12.6 (n=362)	3.06 (1.84-5.07)	<0.0001
CRPA	6.4 (n=202)	2.9 (n=83)	2.44 (1.24-4.81)	0.0099
3GCREC ***	15.8 (n=496)	8.2 (n=236)	1.86 (1.20-2.88)	0.0056
3GCRKP ***	15.9 (n=497)	6.1 (n=176)	2.50 (1.60-3.90)	0.0001
CREC	0.8 (n=26)	0.6 (n=16)	1.48 (0.63-3.48)	0.37
CRKP	3.1 (n=96)	1.0 (n=30)	2.64 (1.10-6.33)	0.029
MRSA	9.0 (n=283)	3.8 (n=109)	2.06 (1.19-3.59)	0.010

* Community-origin (Hospital-origin) BSI was defined for patients in the hospital within (longer than) the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. **The comparison was made using mixed-effect Poisson regression models of patients nested within hospitals. *** For the analysis of mortality, patients with 3GCREC BSI did not include patients with CREC BSI, and patients with 3GCRKP did not include patients with CRKP BSI.

Supplementary File 9. Mortality rate of AMR BSI per 100,000 patient-days at risk

Pathogens *	Tertiary-care hospitals (n of patient-days at risk = 12,341,585)	Secondary-care hospitals (n of patient-days at risk = 9,988,198)	Mortality rate ratio (95% confidence interval) **	P value **
Hospital-origin BSI (per 100,000 patient-days at risk)				
CRAB	10.2 (n=1,261)	3.6 (n=362)	2.77 (1.71-4.48)	<0.0001
CRPA	1.6 (n=202)	0.8 (n=83)	2.16 (1.13-4.13)	0.020
3GCREC ***	4.0 (n=496)	2.4 (n=236)	1.71 (1.14-2.57)	0.0091
3GCRKP ***	4.0 (n=497)	1.8 (n=176)	2.24 (1.49-3.38)	<0.0001
CREC	0.2 (n=26)	0.2 (n=16)	1.28 (0.56-2.99)	0.56
CRKP	0.8 (n=96)	0.3 (n=30)	2.38 (1.03-5.48)	0.042
MRSA	2.3 (n=283)	1.1 (n=109)	1.84 (1.08-3.11)	0.023

* Hospital-origin BSI was defined for patients in the hospital longer than the first two calendar days of admission when the first blood specimens culture positive for a pathogen were taken, with calendar day one equal to the day of admission. Patients were considered at risk of hospital-origin BSI after they stayed in the hospital for more than two calendar days. **The comparison was made using mixed-effect Poisson regression models of patients nested within hospitals. *** For the analysis of mortality, patients with 3GCREC BSI did not include patients with CREC BSI, and patients with 3GCRKP did not include patients with CRKP BSI.

Supplementary File 10. Total number and mortality of patients with notifiable bacterial diseases

Pathogens*	Total number of patients	Total number of in-hospital deaths	In-hospital mortality (%)
<i>Burkholderia pseudomallei</i>	6,164	1,524	24.7%
<i>Brucella</i> spp.	4	0	0%
<i>Corynebacterium diphtheriae</i>	40	9	22.5%
<i>Neisseria gonorrhoeae</i>	60	0	0%
<i>Neisseria meningitidis</i>	13	3	23.1%
Non-typhoidal <i>Salmonella</i> spp.	11,264	1,005	8.9%
<i>Salmonella enterica</i> serovar Paratyphi	30	4	13.3%
<i>Salmonella enterica</i> serovar Typhi	115	4	3.5%
<i>Shigella</i> spp.	361	7	1.9%
<i>Streptococcus suis</i>	710	85	12.0%
<i>Vibrio</i> spp,	2,143	172	8.0%

* Notifiable bacterial diseases were defined as culture positive for pathogens of interest in any type of clinical specimens including blood, cerebrospinal fluid, respiratory tract specimens, urine, genital swab, stool and other or unknown sample types. The AMASS application merged the microbiology data file and hospital admission data file. The merged dataset was then de-duplicated so that only the first isolate per patient per specimen per reporting period was included in the analysis. In-hospital mortality (%) was calculated as the percentage of patients with new AMR BSI who died in the hospitals.